Sutro Biopharma is a clinical stage oncology company developing site-specific antibody drug conjugates (ADCs) enabled by its proprietary XpressCF cell-free protein synthesis platform and XpressCF+ conjugation platform. Its lead product candidate, STRO-004, is a tissue factor-targeting ADC in Phase 1 for solid tumors. Preclinical assets include STRO-227 (PTK7 dual-payload ADC) and STRO-006 (ITG6 ADC). The company has entered collaborations with Astellas, Merck, BMS/Celgene, and EMD Serono for iADCs, cytokine derivatives, BCMA ADCs, and MUC1-EGFR ADCs, and has received approximately $1.016 billion in aggregate collaboration payments through December 31, 2025.
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001193125-26-119873 | EDGAR | 106K words |
| 2025-03-13 | 2024-12-31 | 0000950170-25-038884 | EDGAR | 103K words |
| 2024-03-25 | 2023-12-31 | 0000950170-24-035949 | EDGAR | 112K words |
| 2023-03-30 | 2022-12-31 | 0000950170-23-010976 | EDGAR | 113K words |
| 2022-02-28 | 2021-12-31 | 0000950170-22-002312 | EDGAR | 108K words |
| 2021-03-18 | 2020-12-31 | 0001564590-21-013945 | EDGAR | 106K words |
| 2020-03-16 | 2019-12-31 | 0001564590-20-010890 | EDGAR | 100K words |
| 2019-04-01 | 2018-12-31 | 0001564590-19-010253 | EDGAR | 100K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-11-12 | 2026-09-30 | 0001193125-26-458680 | EDGAR | 72K words |
| 2026-08-12 | 2026-06-30 | 0001193125-26-345748 | EDGAR | 71K words |
| 2025-11-06 | 2025-09-30 | 0001193125-25-270036 | EDGAR | 71K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105219 | EDGAR | 70K words |
| 2025-05-08 | 2025-03-31 | 0000950170-25-067072 | EDGAR | 66K words |
| 2024-11-13 | 2024-09-30 | 0000950170-24-126407 | EDGAR | 71K words |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096336 | EDGAR | 70K words |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058718 | EDGAR | 67K words |
| 2023-11-13 | 2023-09-30 | 0000950170-23-063037 | EDGAR | 77K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041416 | EDGAR | 74K words |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021976 | EDGAR | 69K words |
| 2022-11-08 | 2022-09-30 | 0000950170-22-023279 | EDGAR | 74K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-11-12 | 0001193125-26-458641 | EDGAR | 2K words |
| 2026-08-12 | 0001193125-26-345733 | EDGAR | 3K words |
| 2026-03-23 | 0001193125-26-119844 | EDGAR | 3K words |
| 2026-02-10 | 0001193125-26-044934 | EDGAR | 3K words |
| 2025-12-17 | 0001193125-25-322859 | EDGAR | 1K words |
| 2025-12-03 | 0001193125-25-306786 | EDGAR | 1K words |
| 2025-11-06 | 0001193125-25-269833 | EDGAR | 2K words |
| 2025-09-29 | 0001193125-25-223434 | EDGAR | 1K words |
| 2025-08-07 | 0000950170-25-105159 | EDGAR | 2K words |
| 2025-06-25 | 0000950170-25-089978 | EDGAR | 1K words |
144 total filings indexed. 114 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001382101 |
| Ticker | STRO |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.sutrobio.com |
| Listed | 2018-09-27 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/STRO (~200 tokens, structured JSON with cryptographic provenance)